(NASDAQ: ADVM) Adverum Biotechnologies's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.6%.
Adverum Biotechnologies's earnings in 2025 is -$130,927,000.On average, 6 Wall Street analysts forecast ADVM's earnings for 2025 to be -$109,606,396, with the lowest ADVM earnings forecast at -$146,233,780, and the highest ADVM earnings forecast at -$70,610,025. On average, 4 Wall Street analysts forecast ADVM's earnings for 2026 to be -$90,456,038, with the lowest ADVM earnings forecast at -$136,833,037, and the highest ADVM earnings forecast at -$42,616,702.
In 2027, ADVM is forecast to generate -$149,994,077 in earnings, with the lowest earnings forecast at -$149,994,077 and the highest earnings forecast at -$149,994,077.